Pfizer Jumps
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the activist investor’s unfolding proxy fight. | Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan.
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...
U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla ...
Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term ...
Its high debt load remained a cause of investor concern for the entire year, and as a result, CEO Albert Bourla’s turnaround strategy is now a key part of Pfizer Inc. (NYSE:PFE)’s hypothesis.
Pfizer (PFE) CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the investor disclosed a stake in the company and ...
Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback